AIMS/HYPOTHESIS: Reduced bioavailability of nitric oxide (NO) is a hallmark of diabetes mellitus-induced vascular complications. In the present study we investigated whether a pharmacological increase of endothelial NO synthase (eNOS) production can restore the impaired hindlimb flow in a rat model of severe diabetes. METHODS: A model of diabetes mellitus was induced in male Sprague-Dawley rats by a single injection of streptozotozin. Rats were treated chronically with the eNOS transcription enhancer AVE3085 (10 mg [kg body weight](-1) day(-1); p.o.) or vehicle for 48 days and compared with controls. Endothelial function and arterial BP were investigated in vivo using an autoperfused hindlimb model and TIP-catheter measurement, respectively. Protein production of eNOS, total and phosphorylated vasodilator-stimulated phosphoprotein (VASP) were assessed in their quadriceps muscle tissue, whereas cyclic GMP (cGMP) concentrations were assessed in blood plasma. RNA levels of intracellular and vascular cell adhesion molecules (ICAM-1 and VCAM-1) were measured by real-time PCR. RESULTS: Untreated diabetic rats showed significantly reduced quadriceps muscle contents of eNOS (-64%) and phosphorylated VASP (-26%) protein associated with impaired vascular function (maximum vasodilatation: -30%, p < 0.05) and enhanced production of ICAM-1 (+121%) and VCAM-1 (+156%). Chronic treatment with AVE3085 did not alter arterial BP or severe hyperglycaemia, but did lead to significantly increased production of eNOS (+95%), cGMP (+128%) and VASP phosphorylation (+65%) as well as to improved vascular function (+36%) associated with reduced production of ICAM-1 (-36%) and VCAM-1 (-58%). CONCLUSIONS/ INTERPRETATION: In a rat model of severe diabetes, pharmacological enhancement of impaired eNOS production and NO-cGMP signalling by AVE3085 restores altered hindlimb blood flow and prevents vascular inflammation.
AIMS/HYPOTHESIS: Reduced bioavailability of nitric oxide (NO) is a hallmark of diabetes mellitus-induced vascular complications. In the present study we investigated whether a pharmacological increase of endothelial NO synthase (eNOS) production can restore the impaired hindlimb flow in a rat model of severe diabetes. METHODS: A model of diabetes mellitus was induced in male Sprague-Dawley rats by a single injection of streptozotozin. Rats were treated chronically with the eNOS transcription enhancer AVE3085 (10 mg [kg body weight](-1) day(-1); p.o.) or vehicle for 48 days and compared with controls. Endothelial function and arterial BP were investigated in vivo using an autoperfused hindlimb model and TIP-catheter measurement, respectively. Protein production of eNOS, total and phosphorylated vasodilator-stimulated phosphoprotein (VASP) were assessed in their quadriceps muscle tissue, whereas cyclic GMP (cGMP) concentrations were assessed in blood plasma. RNA levels of intracellular and vascular cell adhesion molecules (ICAM-1 and VCAM-1) were measured by real-time PCR. RESULTS: Untreated diabeticrats showed significantly reduced quadriceps muscle contents of eNOS (-64%) and phosphorylated VASP (-26%) protein associated with impaired vascular function (maximum vasodilatation: -30%, p < 0.05) and enhanced production of ICAM-1 (+121%) and VCAM-1 (+156%). Chronic treatment with AVE3085 did not alter arterial BP or severe hyperglycaemia, but did lead to significantly increased production of eNOS (+95%), cGMP (+128%) and VASP phosphorylation (+65%) as well as to improved vascular function (+36%) associated with reduced production of ICAM-1 (-36%) and VCAM-1 (-58%). CONCLUSIONS/ INTERPRETATION: In a rat model of severe diabetes, pharmacological enhancement of impaired eNOS production and NO-cGMP signalling by AVE3085 restores altered hindlimb blood flow and prevents vascular inflammation.
Authors: M Oelze; H Mollnau; N Hoffmann; A Warnholtz; M Bodenschatz; A Smolenski; U Walter; M Skatchkov; T Meinertz; T Münzel Journal: Circ Res Date: 2000-11-24 Impact factor: 17.367
Authors: Andreas Schäfer; Ulrike Flierl; Anna Kobsar; Martin Eigenthaler; Georg Ertl; Johann Bauersachs Journal: Arterioscler Thromb Vasc Biol Date: 2006-10-05 Impact factor: 8.311
Authors: Carsten Tschöpe; Thomas Walther; Felicitas Escher; Frank Spillmann; Jing Du; Christine Altmann; Ingolf Schimke; Michael Bader; Carlos F Sanchez-Ferrer; Heinz-Peter Schultheiss; Michel Noutsias Journal: FASEB J Date: 2005-08-29 Impact factor: 5.191
Authors: A Smolenski; A M Burkhardt; M Eigenthaler; E Butt; S Gambaryan; S M Lohmann; U Walter Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1998-07 Impact factor: 3.000
Authors: Christopher B Pattillo; Shyamal C Bir; Billy G Branch; Eric Greber; Xinggui Shen; Sibile Pardue; Rakesh P Patel; Christopher G Kevil Journal: Free Radic Biol Med Date: 2010-11-09 Impact factor: 7.376
Authors: L D Kellenberger; J E Bruin; J Greenaway; N E Campbell; R A Moorehead; A C Holloway; J Petrik Journal: J Oncol Date: 2010-02-17 Impact factor: 4.375
Authors: Qin Yang; Hong-Mei Xue; Wing-Tak Wong; Xiao-Yu Tian; Yu Huang; Stephen K W Tsui; Patrick Ks Ng; Paulus Wohlfart; Huige Li; Ning Xia; Silke Tobias; Malcolm John Underwood; Guo-Wei He Journal: Br J Pharmacol Date: 2011-07 Impact factor: 8.739
Authors: Pingping Hu; Xiaojuan Wu; Alok R Khandelwal; Weimin Yu; Zaicheng Xu; Lili Chen; Jian Yang; Robert M Weisbrod; Kin Sing Stephen Lee; Francesca Seta; Bruce D Hammock; Richard A Cohen; Chunyu Zeng; Xiaoyong Tong Journal: Biochim Biophys Acta Mol Basis Dis Date: 2017-02-07 Impact factor: 5.187